查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595213

帕金森氏症藥物市場：按類型、藥物類別、分銷管道、最終用途分類 - 全球預測 2025-2030

Parkinson's Disease Therapeutics Market by Type (Intestinal Infusion, Oral, Subcutaneous), Drug Class (Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor), Distribution Channel, End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年帕金森氏症藥物市場價值為66.7億美元，預計到2024年將達到72.1億美元，複合年成長率為8.28%，預計到2030年將達到116.4億美元。

帕金森氏症藥物包括旨在控制帕金森氏症患者症狀和改善生活品質的治療方法。這個市場包括藥物療法、手術療法以及新型基因和細胞療法。帕金森氏症是第二常見的神經退化性疾病，隨著人口老化，患者數量不斷增加，這一事實推動了對這些治療的需求。治療方法包括左旋多巴和多巴胺促效劑等藥物到深部腦部刺激等手術介入。最終使用領域包括滿足患者需求和測試新療法的醫院、診所和研究機構。影響市場成長的主要因素包括藥物發現和藥物輸送系統的技術進步、研發活動的活性化以及醫療支出的增加。此外，策略聯盟和個人化醫療的快速成長也代表著重大商機。公司可以透過利用研發夥伴關係關係並專注於奈米技術等創新交付平台來抓住這些機會。然而，市場擴張面臨高昂的治療成本、嚴格的監管要求以及長期藥物潛在副作用的挑戰。我們對帕金森氏症發病機制的了解有限，這使得研究和開發工作更加複雜。識別早期診斷的生物標記、開發非侵入性治療方法以及提高藥物療效和安全性等創新領域的探索時機已經成熟。公司應該投資深度學習和人工智慧技術，以加速藥物發現和針對患者的治療計劃。儘管存在這些挑戰，但在對改進治療方法的持續需求和鼓勵突破的支持性法規環境的推動下，市場本質上是動態的。策略規劃涉及將穩健的研發計劃與適應性監管策略相結合，以應對複雜的情況並確保這一重要醫療保健行業的永續成長。

主要市場統計
基準年[2023] 66.7億美元
預測年份 [2024] 72.1億美元
預測年份 [2030] 116.4億美元
複合年成長率（%） 8.28%

市場動態：揭示快速發展的帕金森氏症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變帕金森氏症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 高齡化社會帕金森氏症患者病率增加
    • 開發新的治療方法和新的微創設備
    • 強大的臨床研究藥物管線
  • 市場限制因素
    • 替代治療的可用性
  • 市場機會
    • 政府研發步伐加快
    • 專利到期為製藥公司帶來的可能性
  • 市場挑戰
    • 帕金森氏症藥物的副作用

波特五力戰略工具駕馭帕金森氏症藥物市場

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解帕金森氏症藥物市場的外部影響

外部宏觀環境因素在塑造帕金森氏症藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解帕金森氏症治療藥物市場的競爭狀況

帕金森氏症藥物市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 帕金森氏症藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估帕金森氏症治療市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃帕金森氏症藥物市場的成功之路

對於希望加強在全球市場的影響力的公司來說，帕金森氏症藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老化社會帕金森氏症發生率增加
      • 開發新的治療方法和新的微創設備
      • 強大的藥物管線正在臨床研究中
    • 抑制因素
      • 替代治療方法的可用性
    • 機會
      • 加速政府研究和開發
      • 專利到期為製藥公司帶來的可能性
    • 任務
      • 帕金森氏症藥物副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章帕金森氏症藥物市場：依類型

  • 腸內注射
  • 口服
  • 皮下的
  • 經皮的

第7章依藥物類別分類的帕金森氏症藥物市場

  • 抗膽鹼能藥
  • 碳度巴/左旋多巴
  • COMT抑制劑
  • 多巴胺受體促效劑
  • MAO抑制劑

第8章帕金森氏症藥物市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章帕金森氏症藥物市場：依最終用途

  • 診所
  • 醫院

第10章 美洲帕金森氏症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區帕金森氏症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲帕金森氏症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbvie, Inc.
  • Acadia Pharmaceuticals Inc.
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • DAIICHI SANKYO COMPANY, LIMITED
  • H. Lundbeck A/S
  • Mylan Inc. by Viatris Inc.
  • Novartis AG
  • Orion Corporation
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceuticals Industries Ltd.
  • UCB SA
  • Wockhardt Limited
Product Code: MRR-036C5CF3B54D

The Parkinson's Disease Therapeutics Market was valued at USD 6.67 billion in 2023, expected to reach USD 7.21 billion in 2024, and is projected to grow at a CAGR of 8.28%, to USD 11.64 billion by 2030.

Parkinson's Disease Therapeutics involves treatments aimed at managing symptoms and improving the quality of life for Parkinson's disease patients. This market encompasses medications, surgeries, and emerging gene and cell therapy approaches. The necessity of these therapies arises from Parkinson's being the second most common neurodegenerative disorder, with a growing patient population due to aging demographics. The application of therapies ranges from pharmaceutical drugs like levodopa and dopamine agonists to surgical interventions such as deep brain stimulation. End-use segments include hospitals, clinics, and research institutes that cater to patient needs and experiment with newer treatments. Key factors influencing market growth include technological advancements in drug discovery and delivery systems, rising R&D activities, and increased healthcare expenditures. Additionally, strategic collaborations and the burgeoning field of personalized medicine present substantial opportunities. Companies can seize these by leveraging partnerships for R&D and focusing on innovative delivery platforms like nanotechnology. However, market expansion is challenged by high treatment costs, stringent regulatory requirements, and potential side effects of long-term medication use. The limited understanding of Parkinson's etiology further complicates R&D efforts. Innovation areas like identifying biomarkers for early diagnosis, developing non-invasive treatment options, and improving drug efficacy and safety are ripe for exploration. Companies should invest in deep learning and AI technologies to accelerate drug discovery and patient-specific treatment plans. Despite these challenges, the market is inherently dynamic, driven by a persistent demand for improved therapies and a supportive regulatory environment encouraging breakthroughs. Strategic planning involves combining robust R&D initiatives with adaptive regulatory strategies to navigate complexities and ensure sustainable growth within this vital healthcare sector.

KEY MARKET STATISTICS
Base Year [2023] USD 6.67 billion
Estimated Year [2024] USD 7.21 billion
Forecast Year [2030] USD 11.64 billion
CAGR (%) 8.28%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Parkinson's Disease Therapeutics Market

The Parkinson's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of Parkinson's disease among aging population
    • Development of new therapies and minimally invasive new devices
    • Strong drug pipeline under clinical research
  • Market Restraints
    • Availability of alternative treatments
  • Market Opportunities
    • Increasing pace of R&D by the government
    • Potential for pharmaceutical companies due to patent expiry
  • Market Challenges
    • Side effects of Parkinson's drugs

Porter's Five Forces: A Strategic Tool for Navigating the Parkinson's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Parkinson's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Parkinson's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Parkinson's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Parkinson's Disease Therapeutics Market

A detailed market share analysis in the Parkinson's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Parkinson's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Parkinson's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Parkinson's Disease Therapeutics Market

A strategic analysis of the Parkinson's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Acadia Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Apotex, Inc., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, Cipla Limited, DAIICHI SANKYO COMPANY, LIMITED, H. Lundbeck A/S, Mylan Inc. by Viatris Inc., Novartis AG, Orion Corporation, Sun Pharmaceutical Industries Limited, Teva Pharmaceuticals Industries Ltd., UCB S.A., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Parkinson's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Transdermal.
  • Based on Drug Class, market is studied across Anticholinergic, Carbidopa/Levodopa, COMT Inhibitor, Dopamine Receptor Agonist, and MAO Inhibitor.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retailer Pharmacy.
  • Based on End Use, market is studied across Clinic and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of Parkinson's disease among aging population
      • 5.1.1.2. Development of new therapies and minimally invasive new devices
      • 5.1.1.3. Strong drug pipeline under clinical research
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing pace of R&D by the government
      • 5.1.3.2. Potential for pharmaceutical companies due to patent expiry
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects of Parkinson's drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Parkinson's Disease Therapeutics Market, by Type

  • 6.1. Introduction
  • 6.2. Intestinal Infusion
  • 6.3. Oral
  • 6.4. Subcutaneous
  • 6.5. Transdermal

7. Parkinson's Disease Therapeutics Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Anticholinergic
  • 7.3. Carbidopa/Levodopa
  • 7.4. COMT Inhibitor
  • 7.5. Dopamine Receptor Agonist
  • 7.6. MAO Inhibitor

8. Parkinson's Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retailer Pharmacy

9. Parkinson's Disease Therapeutics Market, by End Use

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital

10. Americas Parkinson's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Parkinson's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbvie, Inc.
  • 2. Acadia Pharmaceuticals Inc.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex, Inc.
  • 5. Bausch Health Companies Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cipla Limited
  • 8. DAIICHI SANKYO COMPANY, LIMITED
  • 9. H. Lundbeck A/S
  • 10. Mylan Inc. by Viatris Inc.
  • 11. Novartis AG
  • 12. Orion Corporation
  • 13. Sun Pharmaceutical Industries Limited
  • 14. Teva Pharmaceuticals Industries Ltd.
  • 15. UCB S.A.
  • 16. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA/LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR AGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAILER PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 193. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023